# Neuropathic Pain Management

> **NCT01263132** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 104 (actual)

## Conditions studied

- Diabetic Neuropathies
- Polyneuropathies

## Interventions

- **DRUG:** F0434
- **DRUG:** Gabapentin

## Key facts

- **NCT ID:** NCT01263132
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2014-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263132, "Neuropathic Pain Management". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01263132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*